BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TMC435: Phase III amended

Medivir said that after discussions with FDA, the primary endpoint for the double-blind, placebo-controlled, international Phase III QUEST-1 trial has been changed to SVR12 from SVR24. The trial is evaluating 150 mg oral TMC435 daily for 12 weeks plus ...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >